血浆游离DNA鉴别甲状腺结节良恶性
本研究评估血浆游离DNA(cfDNA)水平在甲状腺结节良恶性鉴别中的价值。先以Bethesda 2与Bethesda 5&6患者确定cfDNA cutoff为67.9 ng/mL(AUC 0.992),再在Bethesda 3&4不确定结节中验证,敏感度100%、特异度92.3%,与组织病理分类高度一致(kappa 0.94)。
要点
- cfDNA cutoff 67.9 ng/mL在不确定结节中敏感度100%、特异度92.3%。
- cfDNA分类与组织病理分类高度一致(Cohen's kappa 0.94)。
- cfDNA或可辅助鉴别甲状腺结节良恶性。
核心结论
- 血浆cfDNA估计有助于鉴别甲状腺结节良恶性。
研究设计与样本
- 患者接受超声及超声引导细针穿刺,必要时手术;血浆提取cfDNA并定量。
- 初始分析比较Bethesda 2与Bethesda 5&6的cfDNA水平以确定cutoff。
- 后续分析将cutoff应用于不确定结节以验证预测恶性能力。
主要发现
- 细针穿刺n=119,其中Bethesda 2 n=69、Bethesda 5&6 n=13,均经组织病理确认。
- Bethesda 2与Bethesda 5&6组cfDNA水平分别为22.85 ± 1.27和96.20 ± 8.31 ng/mL。
- cfDNA cutoff 67.9 ng/mL的AUC为0.992(95% CI, 0.97-1.0),敏感度100%、特异度93%。
- 不确定组(Bethesda 3&4)手术恶性n=24、良性n=13,应用cutoff敏感度100%、特异度92.3%。
- cfDNA分类与组织病理分类高度一致(Cohen's kappa 0.94;P < 0.001)。
关键数值与推荐
- cfDNA cutoff 67.9 ng/mL用于鉴别良恶性结节。
- 初始分析AUC 0.992(95% CI, 0.97-1.0),敏感度100%、特异度93%。
- 不确定结节验证敏感度100%、特异度92.3%,Cohen's kappa 0.94(P < 0.001)。
临床怎么用
- 血浆cfDNA或可作为甲状腺结节(尤其不确定结节)良恶性鉴别的辅助手段。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Molecular testing is increasingly used to identify malignancy in thyroid nodules (especially indeterminate category). Measurement of cell-free DNA (cfDNA) levels from plasma has been useful in diagnosis of cancers of other organs/tissues; herein we analyze cfDNA levels in patients with thyroid nodules to explore the possibility of establishing a cutoff for identification of malignancy. METHODS: Patients underwent ultrasonography (USG) and USG-guided fine needle aspiration as well as surgery, where indicated. Cell-free DNA was extracted from plasma and quantified. In initial analysis (determination of cutoff), cfDNA levels were compared between Bethesda 2 and Bethesda 5 &6 to establish a cutoff value that could differentiate malignant from benign nodules. In the subsequent analysis, the aforementioned cutoff was applied (validation of cutoff) to those with indeterminate nodules to check ability to predict malignancy. RESULTS: Fine needle aspiration (n = 119) yielded patients with Bethesda 2 (n = 69) Bethesda 5 & 6 (n = 13) who underwent histopathological confirmation. Cell-free DNA levels in these 2 groups were 22.85 ± 1.27 and 96.20 ± 8.31 (ng/mL) respectively. A cfDNA cutoff of 67.9 ng/mL, with area under the curve of 0.992 (95% CI, 0.97-1.0) with 100% sensitivity and 93% specificity was established to identify malignant lesions. Indeterminate group (Bethesda 3 & 4) underwent surgery (malignant n = 24), (benign n = 13), and using the previously identified cutoff for cfDNA, we were able to identify malignant lesions with a sensitivity of 100% and specificity of 92.3%. There was a very strong agreement between cfDNA-based classification with histopathology-based classification of benign and malignant nodules (Cohen's kappa 0.94; P < 0.001). CONCLUSION: Plasma cfDNA estimation could help differentiate malignant from benign thyroid nodules.
引用
- Dutta S, Tarafdar S, Mukhopadhyay P, et al. Plasma Cell-Free DNA to Differentiate Malignant from Benign Thyroid Nodules. J Clin Endocrinol Metab. 2021. PMID: 33475693. doi:10.1210/clinem/dgab030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。